2566-31-6

Basic information

• Product Name: DIPROPYLGLYCINE
• Synonyms: H-DPG-OH;DI-N-PROPYLGLYCINE;DIPROPYLGLYCINE;4-AMINOHEPTANE-4-CARBOXYLIC ACID;N,N''-Dipropylglycine;2-amino-2-propyl-valeric acid;2-azanyl-2-propyl-pentanoic acid;2-Propyl-DL-norvaline
• CAS NO: 2566-31-6
• Molecular Formula: C₈H₁₇NO₂
• Molecular Weight: 159.23
• Product Categories: Unusual amino acids;Amino Acids
• Mol File: 2566-31-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: >300 °C
• Boiling Point: 260.9 °C at 760 mmHg
• Flash Point: 111.6 °C
• Appearance: /
• Density: 1.001 g/cm³
• Vapor Pressure: 0.00356mmHg at 25°C
• Refractive Index: 1.467
• Storage Temp.: Store at RT.
• PKA: 2.58±0.40(Predicted)
• CAS DataBase Reference: DIPROPYLGLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: DIPROPYLGLYCINE(2566-31-6)
• EPA Substance Registry System: DIPROPYLGLYCINE(2566-31-6)

Safety Data

• Hazardous Substances Data: 2566-31-6(Hazardous Substances Data)

Usage

General Description

Dipropylglycine, also known as bis(2-propyl)glycine, is a chemical compound with the molecular formula C7H15NO2. It is an amino acid derivative that is not naturally occurring in the body and is primarily used in pharmaceutical research and development. Dipropylglycine has been investigated for its potential application in the treatment of various neurological disorders, including epilepsy and neuropathic pain. It has also been studied for its potential analgesic and anti-inflammatory effects. While there is ongoing research into the therapeutic potential of dipropylglycine, its exact mechanisms of action and clinical usage are still being explored.

InChI:InChI=1/C8H17NO2/c1-3-5-8(9,6-4-2)7(10)11/h3-6,9H2,1-2H3,(H,10,11)

Upstream product

• 87113-24-4 dipropyl-malonic acid monoamide 
• 36033-33-7 5,5-dipropylimidazolidine-2,4-dione 
• 6148-32-9 2-amino-2-propyl-valeric acid ethyl ester 
• 123-19-3 4-heptanone 
• 151-50-8 potassium cyanide 

Downstream Products

• 84047-60-9 N-benzyloxycarbonyldipropylglycine 

Relevant articles and documents

Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acids

Previous structure-activity and NMR studies on nociceptin/orphanin FQ (N/OFQ) demonstrated that Aib substitution of Ala7 and/or Ala11 increases the peptide potency through an alpha helix structure induction mechanism. On these bases we synthesised and evaluated pharmacologically in the mouse vas deferens assay a series of N/OFQ-NH2 analogues substituted in position 7 and 11 with Cα,α-disubstituted cyclic, linear and branched amino acids. None of the 20 novel N/OFQ analogues produced better results than [Aib7]N/OFQ-NH2. Thus, this substitution was combined with other chemical modifications known to modulate peptide potency and/or efficacy generating compound 21 [Nphe1Aib7Arg14Lys15]N/OFQ-NH2 (coded as UFP-111), compound 22 [(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-112) and compound 23 [Phe1Ψ(CH2-NH)Gly2(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-113). These novel peptides behaved as highly potent NOP receptor ligands showing full (UFP-112) and partial (UFP-113) agonist and pure antagonist (UFP-111) activities in a series of in vitro functional assays performed on pharmacological preparations expressing native as well as recombinant NOP receptors.